Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients

AIDS Research and Human Retroviruses

Volumn 21, Issue 11, 2005, Pages 922-926

  Pogany K ^a   Zaaijer, H L ^a   Prins, J M ^a   Wit, F W ^a   Lange, J M A ^a   Beld, M G H M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LIVER ENZYME; VIRUS DNA;

ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA SEQUENCE; ENZYME BLOOD LEVEL; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION;

ADULT; AMINO ACID SUBSTITUTION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; SEQUENCE ANALYSIS, DNA;

EID: 28944446603     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.922     Document Type: Article

References (29)

1. Noborg U, Gusdal A, Horal P, and Lindh M: Levels of viraemia in subjects with serological markers of past or chronic hepatitis B virus infection. Scand J Infect Dis 2000;32:249-252.
2. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, and Paterlini-Brechot P: Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely "occult"? Hepatology 2001;34:194-203.
3. Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, and Opravil M: Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Eur J Clin Microbiol Infect Dis 1998;17:6-13.
4. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, Omura M, Hikiji K, and Kato M: Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003;37:1172-1179.
5. den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, and Lange JM: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-3902.
6. Wit FW, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, Schuijtemaker J, Eyssen X, Fortuin D, Weeda M, de Wolf F, Reiss P, Danner SA, and Lange JM: Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999;179:790-798.
7. From the Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993;269:729-730.
8. AIDS Clinical Trial Group: Table of grading severity of adult adverse experiences. Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 1996.
9. Torbenson M and Thomas DL: Occult hepatitis B. Lancet Infect Dis 2002;2:479-486.
10. van Steenbergen JE: Results of an enhanced-outreach programme of hepatitis B vaccination in the Netherlands (1998-2000) among men who have sex with men, hard drug users, sex workers and heterosexual persons with multiple partners. J Hepatol 2002;37:507-513.
11. Koppelman MH and Zaaijer HL: Diversity and origin of hepatitis B virus in Dutch blood donors. J Med Virol 2004;73:29-32.
12. Wit FW, Weverling GJ, Weel J, Jurriaans S, and Lange JM: Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002;186:23-31.
13. Alhababi F, Sallam TA, and Tong CY: The significance of 'anti-HBc only' in the clinical virology laboratory. J Clin Virol 2003;27:162-169.
14. Santos EA, Yoshida CF, Rolla VC, Mendes JM, Vieira IF, Arabe J, and Gomes SA: Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 2003;22:92-98.
15. Wagner AA, Denis F, Weinbreck P, Loustaud V, Autofage F, Rogez S, and Alain S: Serological pattern 'anti-hepatitis B core alone' in HIV or hepatitis C virus-infected patients is not fully explained by hepatitis B surface antigen mutants. AIDS 2004;18:569-571.
16. Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, and Barrio E: Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection. Am J Gastroenterol 2000;95:1316-1322.
17. Kao JH, Chen PJ, Lai MY, and Chen DS: Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002;40:4068-4071.
18. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, and Raimondo G: Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-26.
19. Piroth L, Binquet C, Vergne M, Minello A, Livry C, Bour JB, Buisson M, Duong M, Grappin M, Portier H, and Chavanet P: The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol 2002;36:681-686.
20. Greub G and Frei PC: Isolated antibody to hepatitis B core is associated with hepatitis C virus co-infection. Clin Microbiol Infect 2000;6:629.
21. Kao JH, Chen PJ, Lai MY, and Chen DS: Hepatitis D virus genotypes in intravenous drug users in Taiwan: Decreasing prevalence and lack of correlation with hepatitis B virus genotypes. J Clin Microbiol 2002;40:3047-3049.
22. Kao JH, Chen PJ, Lai MY, and Chen DS: Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. J Med Virol 2002;68:216-220.
23. Grethe S, Monazahian M, Bohme I, and Thomssen R: Characterization of unusual escape variants of hepatitis B virus isolated from a hepatitis B surface antigen-negative subject. J Virol 1998;72:7692-7696.
24. Carman WF: Molecular variants of hepatitis B virus. Clin Lab Med 1996;16:407-428.
25. Jongerius JM, Wester M, Cuypers HT, van Oostendorp WR, Lelie PN, van der Poel CL, and van Leeuwen EF: New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion 1998;38:56-59.
26. Allain JP: Occult hepatitis B virus infection. Transfus Clin Biol 2004;11:18-25.
27. Ireland JH, O'Donnell B, Basuni AA, Kean JD, Wallace LA, Lau GK, and Carman WF: Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. Hepatology 2000;31:1176-1182.
28. Seddigh-Tonekaboni S, Waters JA, Jeffers S, Gehrke R, Ofenloch B, Horsch A, Hess G, Thomas HC, and Karayiannis P: Effect of variation in the common "a" determinant on the antigenicity of hepatitis B surface antigen. J Med Virol 2000;60:113-121.
29. Coleman PF, Chen YC, and Mushahwar IK: Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 1999;59:19-24.